Oragenics Stock Price, News & Analysis

Oragenics, Inc. (AMEX: OGEN) announced that its 2021 financial statements contained an unqualified audit opinion with a going concern paragraph. This follows compliance with NYSE American regulations regarding audit opinions. The statements reflect no changes or amendments. Oragenics develops infectious disease treatments, including the NT-CoV2-1 intranasal COVID-19 vaccine and a lantibiotics program targeting antibiotic-resistant bacteria. Investors are cautioned about reliance on forward-looking statements due to inherent risks.

Oragenics, Inc. (AMEX: OGEN) has initiated a GLP toxicology study for its NT-CoV2-1 vaccine candidate, targeting safety and immunogenicity in rabbits. This study aims to gather IND-enabling data for human trials. Conducted by Frontage Laboratories, results are expected by August. The vaccine's intranasal delivery may reduce transmission of COVID-19. Previously, NT-CoV2-1 showed protective results in hamsters. The company focuses on combating infectious diseases, leveraging NIH and NRC research for its vaccine development.

Oragenics, Inc. (NYSE American: OGEN) has partnered with KBI Biopharma to manufacture materials for its intranasal vaccine candidate NT-CoV2-1, which targets SARS-CoV-2. The collaboration includes a 200L demonstration and a 500L cGMP run, positioning Oragenics for a future Phase 2 clinical trial. This vaccine aims to enhance protection at the viral entry points in the respiratory tract, potentially reducing transmission compared to traditional intramuscular vaccines. Previous preclinical trials showed significant immune responses and viral load reductions.

Oragenics, Inc. (NYSE American: OGEN) has released a preprint manuscript detailing its intranasal vaccine, NT-CoV2-1, co-developed with Inspirevax and Canada's NRC. The study found that this vaccine formulation is immunogenic and effective in lowering viral loads in hamsters while generating strong antibody responses in both mice and hamsters. The results support continued development, aiming for FDA submission to advance towards human trials. The intranasal delivery method could enhance protection against COVID-19 compared to traditional vaccines.

Oragenics, Inc. (NYSE American: OGEN) announced that its reconvened Annual Meeting on January 25, 2022 was again adjourned due to insufficient quorum. The meeting has been rescheduled to February 25, 2022, at 4:00 p.m. Eastern Time. Currently, approximately 40% of outstanding shares have submitted proxies. The company has engaged Alliance Advisors to assist in soliciting votes. Shareholders are encouraged to vote by February 24, 2022, to achieve the required majority for proposals in the proxy statement filed on October 13, 2021.

Oragenics, Inc. (NYSE American: OGEN) has extended its licensing and collaboration agreement with the National Research Council of Canada to develop an intranasal vaccine targeting the SARS-CoV-2 Omicron variant. This partnership enables rapid production of spike protein antigens, reducing production time from months to weeks. Oragenics has shown promising results in preclinical studies, demonstrating protection in hamsters against SARS-CoV-2, paving the way for future human clinical trials.

Oragenics, Inc. (NYSE American: OGEN) will participate in Alliance Global Partners' Virtual Series on December 14, 2021, at 1:00 p.m. Eastern time. Executive Chairman Frederick W. Telling, Ph.D., will be interviewed about the Company’s Terra CoV-2 program and its SARS-CoV-2 vaccine candidate. Interested parties can register for the live webcast and replay requests can be made via email. Oragenics focuses on combating infectious diseases with its lead product, Terra CoV-2, aimed at preventing COVID-19 and its variants.

Oragenics, Inc. (AMEX: OGEN), in collaboration with Florida International University, published a study on antimicrobial lanthipeptides in the Journal of Chemical Theory and Computation. The research highlights the urgent need for new antibiotics amidst rising resistance to current treatments. Oragenics is developing lantibiotics that affect bacterial cell walls and membranes, showcasing their potential against antibiotic-resistant infections. The company aims to broaden its lantibiotic pipeline to combat Gram-negative infections while advancing its COVID-19 vaccine candidate, Terra CoV-2.

Oragenics, Inc. (NYSE American: OGEN) announced positive results from a hamster challenge study assessing its SARS-CoV-2 vaccine candidate. Both intranasal and intramuscular formulations demonstrated robust immune responses, successfully reducing viral loads to undetectable levels. The company plans to focus on the intranasal delivery route, citing advantages such as ease of distribution and potential for mucosal immunity. This study will support their Investigational New Drug filing to the FDA, expected in Q2 2022, advancing the program into human clinical trials.